A 96-week subgroup analysis from the PULSAR phase 3 trial, which demonstrated that aflibercept 8 mg (Eylea HD; Regeneron) administered every 12 weeks or longer provided similar visual and anatomic improvements compared to aflibercept 2 mg (Eylea; Regeneron) every 8 weeks in treatment-naïve wet AMD patients, was presented at ARVO 2024. The study analyzed the effect of baseline characteristics such as BCVA, central subfield retinal thickness (CRT), choroidal neovascularization (CNV) type, and race on the efficacy of the treatments.

Patients were randomized into 3 groups: aflibercept 8 mg every 12 or 16 weeks and aflibercept 2 mg every 8 weeks, following 3 initial monthly injections. Results showed that BCVA gains and CRT reductions at week 96 were consistent across all subgroups, irrespective of baseline BCVA, CRT quartiles, CNV type, and race. These findings suggest that aflibercept 8 mg with extended dosing intervals is as effective as the more frequent 2 mg dosing, offering a comparable therapeutic benefit in diverse patient populations.